White House fires all members of the U.S. Commission of Fine Arts, clearing the way for contested building plans.
Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
White House fires all members of the U.S. Commission of Fine Arts, clearing the way for contested building plans.
Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.